BioAsset

Insights / All articles

Research

Update: Replimune Stock Surges

By Alay Galvankar, Lead Analyst & Vice President at BioAsset · 1 slide

The FDA is giving RP1 a “third” chance. Replimune (REPL) announced that it has aligned with the FDA on a path forward for resubmitting its application for RP1, and the agency has agreed to treat the review as an urgent matter. Shares spiked over 90% on Friday.

The news comes directly on the heels of FDA Commissioner Marty Makary’s departure earlier this month. Makary was the commissioner whose agency had rejected the drug twice.

This article is the text version of a BioAsset slide post. See the original slides on bioasset.info.